Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Joshua Geltz"'
Autor:
Michael S. Bosmeny, Adam A. White, Adrian A. Pater, Jennifer Crew, Joshua Geltz, Keith T. Gagnon
Publikováno v:
Virology Journal, Vol 20, Iss 1, Pp 1-10 (2023)
Abstract Insufficient tracking of virus introduction, spread, and new lineage emergence for the human monkeypox (mpox) virus 1 (hMPXV1) outbreak of 2022 hindered epidemiological studies and public health response. hMPXV1 mutations accumulated unexpec
Externí odkaz:
https://doaj.org/article/e313a68c883e483797a2c45c88b2b337
Autor:
Christopher B Chambers, William P Halford, Joshua Geltz, Olga Villamizar, Jeffrey Gross, Alison Embalabala, Edward Gershburg, Andrew Wilber
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0122253 (2015)
Expression systems used to study the biological function of a gene of interest can have limited utility due to three major factors: i) weak or heterogeneous gene expression; ii) poorly controlled gene expression; and iii) low efficiencies of stable i
Externí odkaz:
https://doaj.org/article/74538f029ea44fd2b4686758960c029e
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0145228 (2015)
Herpes simplex virus 2 (HSV-2) 0ΔNLS is a live HSV-2 ICP0- mutant vaccine strain that is profoundly attenuated in vivo due to its interferon-hypersensitivity. Recipients of the HSV-2 0ΔNLS vaccine are resistant to high-dose HSV-2 challenge as evide
Externí odkaz:
https://doaj.org/article/32d1c60b8fa54eb1a6df3ca7dab874ae
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131420 (2015)
Herpes simplex virus type 1 (HSV-1) encodes two bona fide serine/threonine protein kinases, the US3 and UL13 gene products. HSV-1 ΔUS3 mutants replicate with wild-type efficiency in cultured cells, and HSV-1 ΔUL13 mutants exhibit
Externí odkaz:
https://doaj.org/article/1ecd62b2ca4b4516a5ea4c520fdaf32a
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e65523 (2013)
We lack a correlate of immunity to herpes simplex virus 2 (HSV-2) that may be used to differentiate whether a HSV-2 vaccine elicits robust or anemic protection against genital herpes. This gap in knowledge is often attributed to a failure to measure
Externí odkaz:
https://doaj.org/article/f575dc871cde43acadce19613a3af30c
Autor:
Jennifer Lee Wu, Derek J. Royer, Daniel J.J. Carr, Hem R. Gurung, William P. Halford, Jeremy K. Jinkins, Joshua Geltz
Correlates of immunologic protection requisite for an efficacious herpes simplex virus 1 (HSV-1) vaccine remain unclear with respect to viral pathogenesis and clinical disease. In the present study, mice were vaccinated with a novel avirulent, live a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc3b443c4f4465e51cfb370e793759f
https://europepmc.org/articles/PMC4934733/
https://europepmc.org/articles/PMC4934733/
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 12, p e0145228 (2015)
PLoS ONE, Vol 10, Iss 12, p e0145228 (2015)
Herpes simplex virus 2 (HSV-2) 0ΔNLS is a live HSV-2 ICP0 - mutant vaccine strain that is profoundly attenuated in vivo due to its interferon-hypersensitivity. Recipients of the HSV-2 0ΔNLS vaccine are resistant to high-dose HSV-2 challenge as evid
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 6, p e0131420 (2015)
PLoS ONE, Vol 10, Iss 6, p e0131420 (2015)
Herpes simplex virus type 1 (HSV-1) encodes two bona fide serine/threonine protein kinases, the US3 and UL13 gene products. HSV-1 ΔUS3 mutants replicate with wild-type efficiency in cultured cells, and HSV-1 ΔUL13 mutants exhibit
Autor:
Olga Villamizar, Andrew Wilber, Jeffrey Gross, Alison Embalabala, Edward Gershburg, William P. Halford, Joshua Geltz, Christopher B. Chambers
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 3, p e0122253 (2015)
PLoS ONE, Vol 10, Iss 3, p e0122253 (2015)
Expression systems used to study the biological function of a gene of interest can have limited utility due to three major factors: i) weak or heterogeneous gene expression; ii) poorly controlled gene expression; and iii) low efficiencies of stable i
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 6, p e65523 (2013)
PLoS ONE, Vol 8, Iss 6, p e65523 (2013)
We lack a correlate of immunity to herpes simplex virus 2 (HSV-2) that may be used to differentiate whether a HSV-2 vaccine elicits robust or anemic protection against genital herpes. This gap in knowledge is often attributed to a failure to measure